… the current dose was safe and to dose escalate and could decide to skip a dose if it did
not more than double and was deemed safe by the Bayesian model. Once the dose-escalation …

… This study was an extension to the phase 1 main study, which was a prospective, open-label,
dose-escalation study to evaluate the safety and immunogenicity of a SARS-CoV-2 …

… are performed for different purposes with a single preliminary dose escalation study. Once
a relatively low endpoint is met, the dose escalation study identifies the dose for a first, low-…

… , dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes
the stabilized prefusion SARS-CoV… sequentially to receive two doses of either 25 μg or 100 …

… We conducted a phase 1, dose-escalation, open-label clinical trial designed to determine …
dose of 25 μg, 100 μg, or 250 μg. On the basis of the results obtained in patients at these dose …

… 2 weeks after completion of the two-dose priming schedule, showed significantly higher
GMTs of SARS-CoV-2 neutralizing antibody titres in the highest dose group (GMT 545.6; 95% CI…

… We report results of a proof of concept, open-label, dose-escalation vaccine trial, and
show … In this study, we showed that a two-dose regimen of 10 µg or 20 µg mRNA SARS-CoV-2 …

… We also measured the neutralising antibody responses induced by vaccination using
both live SARS-CoV-2 virus neutralisation (virus strain SARS-CoV-2/human/CHN/Wuhan_IME-…

… This study was a dose escalation study with three separate groups of participants 20 to
49 years of age. Each sub-phase consisted of 15 participants. The three different …

… -RBD LAIV vaccine could elicit mucosal immunity against SARS-CoV-2, as the vaccine was
… The saliva total Ig against SARS-CoV-2 RBD of the high-dose vaccine was significantly …